HOME >> BIOLOGY >> NEWS
Nature's path leads scientists to new antibiotic strategy

MADISON - By mimicking one of nature's own potent antimicrobial defenses, scientists may have found a new way to wage war on pathogenic bacteria.

Writing this week (April 6) in the British scientific journal Nature, a team of scientists from the University of Wisconsin-Madison report the design, synthesis and evaluation of a new type of molecule that exhibits a wide spectrum of antimicrobial activity, including against two species of bacteria that are resistant to common antibiotic drugs.

The work is important because it demonstrates the feasibility of developing a new class of antibiotics that can potentially overcome the growing resistance of disease-causing bacteria to current medicines, according to UW-Madison chemistry Professor Samuel H. Gellman, an author of the new study. Moreover, the work reveals the potential of using nature as a guide to build medically important synthetic molecules that can outperform their naturally-occurring counterparts.

"Nearly all antimicrobial agents now used in clinical settings are naturally-occurring molecules, or are closely related to molecules found in nature," Gellman said. "In contrast, our new antimicrobials are very different from all molecules found in nature. The upshot of this research is that we may be on a radical new path that may lead to the rational, deliberate design of clinically useful molecules like antibiotics."

The design of the new antibacterial agents involved mimicry of naturally-occurring peptides that ward off microbial invasion.

Peptides are composed of alpha-amino acids which also are the building blocks of protein molecules and are essential to all life. In nature, peptides can be selectively toxic to invading microorganisms, forming a first line of antimicrobial defense in everything from plants to people. The natural antibiotic peptides, however, are rapidly degraded in living tissues and can be highly toxic to human cells in addition to infectious
'"/>

Contact: Samuel H. Gellman
gellman@chem.wisc.edu
608-262-3303
University of Wisconsin-Madison
4-Apr-2000


Page: 1 2 3

Related biology news :

1. Natures ambush: pregnancy more likely from single unprotected intercourse than believed
2. Researchers discover structure of Natures circuit breaker
3. Natures own antidote to cocaine
4. Natures own medicine for vision loss: Inhibitor of angiogenesis found by biologists at The Scripps Research Institute
5. Natures chemical weapons save lives
6. Worlds Leading Echinacea Researchers To Examine Latest Scientific Findings On "Natures Gentle Antibiotic"
7. Natures Sugar High
8. Photosynthetic Harvest Inc. Harnesses The Power Of Natures Chemical Factories By "Milking" Green Plants For Valuable Natural Products
9. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction
10. Cockroach-like robot leads new research effort
11. Washington University in St. Louis leads group studying aging process

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nature path leads scientists new antibiotic strategy

(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/9/2015)... Calif. , July 9, 2015 /PRNewswire/ ... leading developer of human interface solutions, today ... the industry,s first fully hardware encapsulated fingerprint ... secure authentication technology is literally off the ... and biometric matching within the fingerprint sensor ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
Cached News: